Retrospective Real-word Study of Linezolid for the Treatment of Tuberculous Meningitis

Learn more about:
Related Clinical Trial
Trial of a Six-Month Regimen of High-Dose Rifampicin, High-Dose Isoniazid, Linezolid, and Pyrazinamide Versus a Standard Nine-Month Regimen for the Treatment of Adults and Adolescents With Tuberculous Meningitis Cyclophosphamide in the Treatment of Refractory Proliferative Arachnoiditis in CNS Tuberculosis Evaluation of New Biomarker-based Approaches for Improving the Diagnosis of Childhood Tuberculous Meningitis Retrospective Real-word Study of Linezolid for the Treatment of Tuberculous Meningitis Study Of The Long Term Outcome Of Tuberculous Meningitis In Vietnamese Adults Treated With Adjunctive Dexamethasone Adjunctive Corticosteroids for Tuberculous Meningitis in HIV-infected Adults (The ACT HIV Trial) The Relationships Between Gene Polymorphisms of LTA4H and Dexamethasone Treatment for Tuberculous Meningitis Linezolid, Aspirin and Enhanced Dose Rifampicin in HIV-TBM Leukotriene A4 Hydrolase Stratified Trial of Adjunctive Corticosteroids for HIV-uninfected Adults With Tuberculous Meningitis Diagnosis of Tuberculous Meningitis by ESAT-6 in CSF Intensified Tuberculosis Treatment to Reduce the Mortality of Patients With Tuberculous Meningitis Optimizing Antituberculosis Therapy in Adults With Tuberculous Meningitis A Pilot Study of Adjunctive Aspirin for the Treatment of HIV Negative Adults With Tuberculous Meningitis Rifampicin Explorative PK Study for Tuberculous Meningitis Comparing Oral and Intravenous Preparation Immediate Versus Deferred Antiretroviral Therapy for HIV-Associated Tuberculous Meningitis

Brief Title

Retrospective Real-word Study of Linezolid for the Treatment of Tuberculous Meningitis

Official Title

Retrospective Real-word Study of Linezolid for the Treatment of Tuberculous Meningitis

Brief Summary

      Tuberculous meningitis (TBM) is the most serious form of Mycobacterium tuberculosis
      infection, causing mortality and disability in more than half of the patients. Current
      standard treatment for TBM is based on those developed to treat pulmonary tuberculosis, which
      does not take into account the differential ability of anti-tuberculosis drugs to penetrate
      the brain. With both good central nervous system penetrance and anti-tuberculosis efficacy
      that have been demonstrated in drug-resistant tuberculosis, linezolid may be a promising
      antimicrobial in TBM treatment. The purpose of this study is to evaluate the effectiveness of
      linezolid in the treatment of TBM.
    



Study Type

Observational


Primary Outcome

Survival

Secondary Outcome

 Number of participants with Medical Research Council grade deterioration

Condition

Tuberculous Meningitis

Intervention

Linezolid

Study Arms / Comparison Groups

 Background group
Description:  The treatment regimen does not include linezolid throughout the treatment course.

Publications

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information


Recruitment Status

Drug

Estimated Enrollment

150

Start Date

January 1, 2018

Completion Date

June 1, 2019

Primary Completion Date

May 1, 2019

Eligibility Criteria

        Inclusion Criteria:

          -  all patients diagnosed as TBM from the electronic medical record system.

        Exclusion Criteria:

          -  Does not meet the established diagnostic criteria;

          -  Combine other pathogen central infections;

          -  Follow-up confirmed that the final diagnosis considers other diseases (such as tumors,
             autoimmune encephalitis, etc.);

          -  Our hospital has less than one week of anti-tuberculosis treatment;

          -  Lack of information
      

Gender

All

Ages

18 Years - N/A

Accepts Healthy Volunteers

No

Contacts

, (86)18801734036, [email protected]

Location Countries

China

Location Countries

China

Administrative Informations


NCT ID

NCT03898635

Organization ID

2017-44


Responsible Party

Principal Investigator

Study Sponsor

Huashan Hospital


Study Sponsor

, , 


Verification Date

March 2019